Healthcare provider profile · identity verified

Jean Marie Decavitch, NP-C

Nurse Practitioner · CEDAR LAKE, IN · NPI 1982956017

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	341	52
Levothyroxine Sodium	Levothyroxine Sodium	252	76
Lisinopril	Lisinopril	223	66
Gabapentin	Gabapentin	204	44
Albuterol Sulfate Hfa	Albuterol Sulfate	203	54
Alprazolam	Alprazolam	199	44
Atorvastatin Calcium	Atorvastatin Calcium	197	66
Amlodipine Besylate	Amlodipine Besylate	191	63
Omeprazole	Omeprazole	126	36
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	120	12
Losartan Potassium	Losartan Potassium	114	40
Sertraline Hcl	Sertraline Hcl	113	34
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	104	26
Clonazepam	Clonazepam	101	19
Montelukast Sodium	Montelukast Sodium	100	29
Pantoprazole Sodium	Pantoprazole Sodium	100	40
Zolpidem Tartrate	Zolpidem Tartrate	99	12
Metformin Hcl	Metformin Hcl	98	31
Furosemide	Furosemide	87	28
Hydrochlorothiazide	Hydrochlorothiazide	85	25
Metoprolol Tartrate	Metoprolol Tartrate	83	25
Tamsulosin Hcl	Tamsulosin Hcl	74	22
Tramadol Hcl	Tramadol Hcl	72	19
Simvastatin	Simvastatin	69	21
Tizanidine Hcl	Tizanidine Hcl	69	18
Azithromycin	Azithromycin	68	56
Prednisone	Prednisone	68	42
Carvedilol	Carvedilol	66	22
Ozempic	Semaglutide	66	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	65	13
Metoprolol Succinate	Metoprolol Succinate	62	17
Diazepam	Diazepam	53	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	53	17
Trazodone Hcl	Trazodone Hcl	50	18
Lorazepam	Lorazepam	49	suppressed
Ondansetron Odt	Ondansetron	49	17
Rosuvastatin Calcium	Rosuvastatin Calcium	49	17
Clopidogrel	Clopidogrel Bisulfate	48	14
Ibuprofen	Ibuprofen	47	13
Alendronate Sodium	Alendronate Sodium	43	12
Methylprednisolone	Methylprednisolone	41	37
Pregabalin	Pregabalin	41	11
Breo Ellipta	Fluticasone/Vilanterol	40	suppressed
Duloxetine Hcl	Duloxetine Hcl	39	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	16
Buspirone Hcl	Buspirone Hcl	33	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	33	suppressed
Potassium Chloride	Potassium Chloride	33	14
Meloxicam	Meloxicam	32	12
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	11
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Cefuroxime	Cefuroxime Axetil	28	25
Ropinirole Hcl	Ropinirole Hcl	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	21
Nystatin	Nystatin	26	15
Enalapril Maleate	Enalapril Maleate	25	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Fentanyl	Fentanyl	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Novolog Flexpen	Insulin Aspart	22	suppressed
Glipizide	Glipizide	21	suppressed
Irbesartan	Irbesartan	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Allopurinol	Allopurinol	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Famotidine	Famotidine	18	suppressed
Linzess	Linaclotide	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	11
Mounjaro	Tirzepatide	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Diclofenac Potassium	Diclofenac Potassium	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Aripiprazole	Aripiprazole	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Atenolol	Atenolol	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Amoxicillin	Amoxicillin	12	11
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Naproxen	Naproxen	12	suppressed
Novolog	Insulin Aspart	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Xifaxan	Rifaximin	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Cephalexin	Cephalexin	11	11
Entresto	Sacubitril/Valsartan	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error